ReviewFrontiers in oncology2018
Multi-Omics Profiling of the Tumor Microenvironment: Paving the Way to Precision Immuno-Oncology.
Review in Frontiers in oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 77 citations in OpenAlex.
- Clinical application of single-cell RNA sequencing in disease and therapy.Clinical and translational medicine · 2025Review
- Immune evasion in cancer: mechanisms and cutting-edge therapeutic approaches.Signal transduction and targeted therapy · 2025Review
- Conditional universal differential equations capture population dynamics and interindividual variation in c-peptide production.NPJ systems biology and applications · 2025Article
- The role of E3 ligases and deubiquitinases in PD-L1 regulation and the tumor microenvironment in renal cell carcinoma.Medical oncology (Northwood, London, England) · 2025Review
- A comprehensive review of cancer survival prediction using multi-omics integration and clinical variables.Briefings in bioinformatics · 2025Review
- Epithelial cell diversity and immune remodeling in bladder cancer progression: insights from single-cell transcriptomics.Journal of translational medicine · 2025Article
- Tumor Cell Communications as Promising Supramolecular Targets for Cancer Chemotherapy: A Possible Strategy.International journal of molecular sciences · 2024Review
- Multimodal analysis unveils tumor microenvironment heterogeneity linked to immune activity and evasion.iScience · 2024Article
- Biomarker development for PD-(L)1 axis inhibition: a consensus view from the SITC Biomarkers Committee.Journal for immunotherapy of cancer · 2024Review
- Single-Cell RNA Sequencing: Technological Progress and Biomedical Application in Cancer Research.Molecular biotechnology · 2024Review
- Emerging measurements for tumor-infiltrating lymphocytes in breast cancer.Japanese journal of clinical oncology · 2024Review
- Isolation of Live Immune Cells from the Tumor Microenvironment by FACS.Methods in molecular biology (Clifton, N.J.) · 2024Article
- The Tumor Immune Microenvironment Architecture Correlates with Risk of Recurrence in Head and Neck Squamous Cell Carcinoma.Cancer research · 2023Article
- Multi-Omics Integration for the Design of Novel Therapies and the Identification of Novel Biomarkers.Proteomes · 2023Review
- Assay-agnostic spatial profiling detects tumor microenvironment signatures: new diagnostic insights for triple-negative breast cancer.Molecular oncology · 2023Article
- Medical gas plasma technology: Roadmap on cancer treatment and immunotherapy.Redox biology · 2023Review
- Comprehensive analysis of single-cell RNA-seq and bulk RNA-seq revealed the heterogeneity and convergence of the immune microenvironment in renal cell carcinoma.Functional & integrative genomics · 2023Article
- Single-Cell Analysis in Immuno-Oncology.International journal of molecular sciences · 2023Review
- Progress in the studies on the molecular mechanisms associated with multidrug resistance in cancers.Acta pharmaceutica Sinica. B · 2023Review
- Immunology of Oral Squamous Cell Carcinoma-A Comprehensive Insight with Recent Concepts.Life (Basel, Switzerland) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
Abstract
The tumor microenvironment (TME) is a multifaceted ecosystem characterized by profound cellular heterogeneity, dynamicity, and complex intercellular cross-talk. The striking responses obtained with immune checkpoint blockers, i.e., antibodies targeting immune-cell regulators to boost antitumor immunity, have demonstrated the enormous potential of anticancer treatments that target TME components other than tumor cells. However, as checkpoint blockade is currently beneficial only to a limited fraction of patients, there is an urgent need to understand the mechanisms orchestrating the immune response in the TME to guide the rational design of more effective anticancer therapies. In this Mini Review, we give an overview of the methodologies that allow studying the heterogeneity of the TME from multi-omics data generated from bulk samples, single cells, or images of tumor-tissue slides. These include approaches for the characterization of the different cell phenotypes and for the reconstruction of their spatial organization and inter-cellular cross-talk. We discuss how this broader vision of the cellular heterogeneity and plasticity of tumors, which is emerging thanks to these methodologies, offers the opportunity to rationally design precision immuno-oncology treatments. These developments are fundamental to overcome the current limitations of targeted agents and checkpoint blockers and to bring long-term clinical benefits to a larger fraction of cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.